Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

  • ID: 4051354
  • Report
  • Region: Asia Pacific
  • 108 Pages
  • GBI Research
1 of 4
Asia-Pacific Seasonal Influenza Vaccines Market to Surpass $1.7 Billion by 2022
Seasonal influenza is a viral disease caused by influenza virus that spreads easily from person to person. Seasonal influenza is characterized by a sudden onset of high fever, cough (usually dry), headache, muscle and joint pain, severe malaise, sore throat and runny nose. The cough can be severe and last two or more weeks. Most people recover from fever and other symptoms within a week without requiring medical attention. But influenza can cause severe illness or death, especially in people at high risk.

Asia-Pacific (APAC) seasonal influenza market is forecast to grow from US$1.24 Billion in 2015 to US$1.71 Billion in 2022, at a compound annual growth rate (CAGR) of 4.7%. The incidence of seasonal influenza is expected to increase significantly across the APAC markets over the forecast period, mainly due to growing elderly populations. Major market drivers are increasing awareness and affordability, rising vaccination coverage in the APAC countries and growing government support for immunization against seasonal influenza.

Marketed seasonal influenza vaccines across the APAC region display various degrees of efficacy in preventing seasonal influenza infection, as well as strong safety profiles. However, the currently available vaccines still display efficacy deficits, particularly in high-risk groups such as the elderly and the immunocompromised.

In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers. Continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus.

The report “Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies” provides an introduction to seasonal influenza, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, prognosis for patients and detailing the key points driving the seasonal influenza market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.

In depth, this report includes the following analysis:
  • Provides an introduction to seasonal influenza, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients.
  • Provides detailed analysis of the drugs currently marketed for this indication: Fluarix Tetra, FluQuadri, Vaxigrip, Agrippal, Fluad, Fluvax/Afluria, Optaflu, Influvac, GC Flu, Intanza/IDflu, SkyCellflu and Nasovac-S.
  • Detailed analysis of the pipeline for seasonal influenza, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Supplies forecasts for the seasonal influenza market for the 2015-2022 period, including epidemiology, treatment usage patterns, pricing and market size. The five Asia-Pacific markets are covered, and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for the seasonal influenza market.
  • Describes the major deals that have taken place in the global seasonal influenza market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.
Companies mentioned in this report: AltraVax, Maxygen, Baxter, Takeda, Roche, Savira Pharmaceuticals, Medicago, Philip Morris Products, ContraFect, Trellis, Shionogi.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Pathophysiology
2.5 Diagnosis
2.6 Prognosis
2.7 Treatment Options
2.7.1 Treatment Algorithm
2.7.2 Pharmacological Treatments
2.7.3 Non-pharmacological Treatments
2.7.4 Exercise
2.7.5 Dietary Interventions

3 Marketed Products
3.1 Overview
3.2 Fluarix Tetra - GlaxoSmithKline
3.3 FluQuadri - Sanofi Pasteur
3.4 Vaxigrip - Sanofi Pasteur
3.5 Agrippal - CSL
3.6 Fluad - CSL
3.7 Fluvax/Afluria - CSL
3.8 Optaflu - CSL
3.9 Influvac - Abbott
3.10 GC Flu - Green Cross Corporation
3.11 Intanza/IDflu - Sanofi Pasteur
3.12 SkyCellflu - SK Chemicals
3.13 Nasovac-S - Serum Institute of India
3.14 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 VN-100 - Daiichi Sankyo
4.4.2 ASP7374 (UMN-0502) - UMN Pharma
4.4.3 MEDI3250 (VN-0107) - Daiichi Sankyo
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Awareness and Affordability of Seasonal Influenza Vaccines
7.1.2 Launch of Quadrivalent Influenza Vaccines
7.1.3 Growing Elderly Population
7.1.4 Expansion of Cell-Cultured Vaccines
7.2 Barriers
7.2.1 Limited Awareness of Influenza’s Threat
7.2.2 Unpredictable Vaccine Demand
7.2.3 Influenza Vaccine Safety Concerns
7.2.4 Decentralized Vaccine Policy and Reimbursement System

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-Development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-Development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.1.6 Pre-registration
9.2 Market Forecasts to 2022
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact
9.7 Disclaimer

1.1 List of Tables

Table 1: Symptoms of Influenza
Table 2: Influenza Testing Methods
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Seasonal Influenza Therapeutics Market, Asia-Pacific, Most Administered Influenza Vaccines by Country
Table 5: Available Antiviral Drugs for Seasonal Influenza
Table 6: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 7: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 8: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 9: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 10: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 11: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016
Table 12: Seasonal influenza Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
Table 13: Seasonal Influenza Therapeutics Market, India, Market Forecast, 2015-2022
Table 14: Seasonal Influenza Therapeutics Market, China, Market Forecast, 2015-2022
Table 15: Seasonal Influenza Therapeutics Market, Australia, Market Forecast, 2015-2022
Table 16: Seasonal Influenza Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 17: Seasonal Influenza Therapeutics Market, Japan, Market Forecast, 2015-2022

1.2 List of Figures

Figure 1: Notifications of Laboratory-Confirmed Influenza, Australia, 2012-July 2016
Figure 2: Seasonal Influenza Therapeutics Market, Treatment Algorithm of Seasonal Influenza
Figure 3: Seasonal Influenza Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Treatment of Seasonal Influenza
Figure 4: Pipeline for Seasonal Influenza Therapeutics by Molecular Type, Global, 2016
Figure 5: Pipeline for Seasonal Influenza Therapeutics by Molecular Target, Global, 2016
Figure 6: Seasonal Influenza Therapeutics Market, Asia-Pacific, VN-100 ($m), 2017-2022
Figure 7: Seasonal Influenza Therapeutics Market, Asia-Pacific, ASP7374 ($m), 2017-2022
Figure 8: Seasonal Influenza Therapeutics Market, Asia-Pacific, MEDI3250 ($m), 2017-2022
Figure 9: Seasonal Influenza Therapeutics Market, Comparative Efficacy Heatmap for Pipeline Products
Figure 10: Seasonal Influenza Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2016
Figure 11: Seasonal Influenza Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 12: Seasonal Influenza Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 13: Seasonal Influenza Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 14: Seasonal Influenza Therapeutics, Global, Clinical Trial Duration by Molecule Type, 2006-2016
Figure 15: Seasonal Influenza Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2016
Figure 16: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2016
Figure 17: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2016
Figure 18: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type, 2006-2016
Figure 19: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2016
Figure 20: Seasonal Influenza Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 21: Seasonal Influenza Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 22: Seasonal Influenza Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2015-2022
Figure 23: Seasonal Influenza Therapeutics Market, Asia-Pacific, Market Size ($bn), 2015-2022
Figure 24: Seasonal Influenza Therapeutics Market, India, Treatment Patterns (million), 2015-2022
Figure 25: Seasonal Influenza Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
Figure 26: Seasonal Influenza Therapeutics Market, India, Market Size ($m), 2015-2022
Figure 27: Seasonal Influenza Therapeutics Market, China, Treatment Patterns (million), 2015-2022
Figure 28: Seasonal Influenza Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
Figure 29: Seasonal Influenza Therapeutics Market, China, Market Size ($m), 2015-2022
Figure 30: Seasonal Influenza Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022
Figure 31: Seasonal Influenza Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
Figure 32: Seasonal Influenza Therapeutics Market, Australia, Market Size ($m), 2015-2022
Figure 33: Seasonal Influenza Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022
Figure 34: Seasonal Influenza Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 35: Seasonal Influenza Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 36: Seasonal Influenza Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
Figure 37: Seasonal Influenza Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
Figure 38: Seasonal Influenza Therapeutics Market, Japan, Market Size ($m), 2015-2022
Figure 39: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 40: Seasonal Influenza Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 41: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 42: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 43: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
Figure 44: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Region, 2006-2016
Figure 45: Seasonal Influenza Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 46: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 47: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2016
Figure 48: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll